Saturday, April 27, 2024, Washington, DC, 6:00 PM – 8:00 PM Eastern Time

What I Tell My Patients: Integrating New Research Information into Current Clinical Care

A Complimentary NCPD Hybrid Symposium Series Held During the 49th Annual ONS Congress

Gastroesophageal and Colorectal Cancers

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Program Schedule — Eastern Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — NCPD Dinner Meeting

Meeting Room
Independence Ballroom (Meeting Level 4)

This event will also be webcast live.
Please see Registration tab for details.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.  
Deanna A Griffie, MSN, AGNP-C
Nurse Practitioner
GI Medical Oncology
Duke Cancer Institute
Durham, North Carolina

Caroline Kuhlman, MSN, APRN-BC
Nurse Practitioner
Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital
Boston, Massachusetts

Manish A Shah, MD
Chief, Solid Tumor Oncology Service
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Bartlett Family Professor
of Gastrointestinal Oncology
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York

John Strickler, MD
Associate Professor
Associate Director, Clinical Research – GI
Duke University
Durham, North Carolina

Neil Love, MD
Research To Practice
Miami, Florida

Meeting space has been assigned to provide a satellite symposium supported by Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, and Taiho Oncology Inc during the Oncology Nursing Society’s (ONS) 49th Annual Congress, April 24-28, 2024 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Eastern Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — NCPD Dinner Meeting


What I Tell My Patients About ...

The Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Nonmetastatic Gastroesophageal Cancers

  • Long-term outcomes achieved with historical treatment approaches for patients with localized/locally advanced gastroesophageal tumors
  • Key efficacy and safety findings with adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction (GEJ) cancer
  • Appropriate selection of candidates for treatment with adjuvant nivolumab

The Potential Role of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Patients with Gastric/GEJ Cancer

  • Early data with immune checkpoint inhibitors as neoadjuvant therapy for resectable microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) gastric/GEJ adenocarcinoma
  • Improvement in pathologic complete response rate with the addition of durvalumab to neoadjuvant FLOT (fluorouracil/leucovorin/oxaliplatin/docetaxel) for patients with resectable gastric/GEJ cancer in the Phase III MATTERHORN trial
  • Ongoing evaluation of perioperative durvalumab in the MATTERHORN study and potential clinical role of this strategy

First-Line Therapy for Metastatic Gastroesophageal Cancers

  • Biological similarities and differences between gastric, GEJ and esophageal cancers; effect of tumor location and histology on management approach
  • Influence of PD-L1 status on the selection of first-line treatment; appropriate timing of and optimal approaches to PD-L1 assessment
  • Published data sets demonstrating the efficacy of first-line nivolumab- and pembrolizumab-containing regimens for advanced gastric, GEJ and esophageal cancer
  • Evidence-based selection of chemotherapy alone versus combined chemoimmunotherapy versus dual immune checkpoint inhibition for patients with newly diagnosed gastroesophageal tumors

The Potential Role of Therapy Targeting Claudin 18.2 (CLDN18.2) for Gastroesophageal Cancers

  • Biological rationale for targeting CLDN18.2 in gastric/GEJ cancers; mechanism of antitumor activity of zolbetuximab
  • Published efficacy and safety findings with zolbetuximab in combination with chemotherapy as first-line therapy for patients with advanced CLDN18.2-positive gastric/GEJ cancer
  • Potential clinical role of up-front zolbetuximab/chemotherapy and implications for biomarker assessment
  • Incidence, severity and timing of nausea and vomiting observed with zolbetuximab for patients with and without prior gastrectomy
  • Role of antiemetics and other supportive care measures for patients receiving zolbetuximab
  • Spectrum, frequency and management of other toxicities reported with zolbetuximab

Targeted Therapies for HER2-Positive Gastroesophageal Cancers

  • Principal outcomes supporting the addition of pembrolizumab to chemotherapy/trastuzumab for previously untreated HER2-positive advanced gastric/GEJ adenocarcinoma; effect of PD-L1 status on eligibility for this approach
  • Published data with trastuzumab deruxtecan (T-DXd) for patients with progressive HER2-positive gastric/GEJ cancer
  • Spectrum, frequency and management of toxicities associated with T-DXd


What I Tell My Patients About ...

Selection of Appropriate Candidates with Localized CRC for Adjuvant Therapy

  • Factors guiding the use of adjuvant chemotherapy for patients with Stage II and Stage III CRC
  • Rationale for the assessment of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) to help inform treatment decision-making for patients with localized CRC
  • Published research data with ctDNA testing to identify patients at increased risk for recurrence who are likely to benefit from adjuvant chemotherapy
  • Active studies examining the clinical utility of ctDNA-based MRD testing for guiding treatment decisions and monitoring recurrence in CRC; current and future clinical role

The Current Role of Immune Checkpoint Inhibitors (ICIs) in the Treatment of Metastatic CRC (mCRC)

  • Incidence of MSI-H/dMMR mCRC; rationale for the activity of ICIs in MSI-H/dMMR tumors
  • Long-term outcomes with front-line pembrolizumab for MSI-H/dMMR mCRC
  • Recently presented findings indicating improved progression-free survival with first-line nivolumab/ipilimumab compared to chemotherapy for patients with MSI-H/dMMR mCRC; potential role of this strategy
  • Rational incorporation of pembrolizumab, nivolumab and nivolumab/ipilimumab into treatment for patients with progressive MSI-H/dMMR mCRC

Tolerability and Other Practical Considerations with ICIs

  • Pathophysiology, spectrum, frequency, severity and timing of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies
  • Effect on the tolerability of anti-PD-1/PD-L1 antibodies when administered in combination with other systemic therapies such as chemotherapy and anti-CTLA-4 antibodies
  • Optimal approaches to monitoring and for and management of immune-related and other AEs with ICIs; differences, if any, for patients with localized versus metastatic disease
  • Optimal duration of immune checkpoint inhibition

The Role of TAS-102/Bevacizumab in the Management of Relapsed/Refractory (R/R) mCRC

  • Long-term findings with TAS-102 monotherapy for patients with multiregimen-relapsed mCRC
  • Published efficacy and safety data with TAS-102 in combination with bevacizumab for patients with R/R mCRC
  • Recent FDA approval of TAS-102/bevacizumab and current clinical role
  • Factors influencing the sequencing of TAS-102 with or without bevacizumab vis-à-vis other available therapies for progressive mCRC, such as regorafenib, EGFR antibodies and fruquintinib
  • Spectrum and frequency of toxicities reported with TAS-102 with or without bevacizumab; recommended monitoring and management protocols

The Integration of Therapies Targeting HER2 into the Management of mCRC

  • Incidence of HER2 amplification/overexpression in patients with mCRC; recommended timing of and appropriate platforms for HER2 testing
  • Pivotal data with tucatinib/trastuzumab for previously treated HER2-positive mCRC
  • Recent FDA approval and current clinical role of tucatinib/trastuzumab
  • Available efficacy and safety findings with T-DXd for patients with HER2-expressing mCRC
  • Current and future nonresearch role of T-DXd

The Potential Role of KRAS-Targeted Therapy in the Management of mCRC

  • Incidence of KRAS G12C mutations in mCRC; mechanism of action of sotorasib and adagrasib
  • Available efficacy and safety data with sotorasib and adagrasib monotherapy for patients with mCRC and KRAS G12C mutations
  • Rationale for combining KRAS-targeted agents with anti-EGFR therapy for mCRC
  • Recently presented findings with sotorasib and panitumumab for patients with chemorefractory mCRC with a KRAS G12C mutation; potential clinical role of this strategy

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastroesophageal and colorectal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise clinical trial findings supporting the use of neoadjuvant and/or adjuvant anti-PD-1/PD-L1 antibody therapy for patients with resectable gastric, gastroesophageal junction (GEJ) and esophageal cancer, and discern the clinical applicability of various treatment strategies.
  • Understand how HER2 status, PD-L1 combined positive score, microsatellite instability/mismatch repair status, claudin 18.2 positivity, clinical factors and patient preferences affect the selection of first-line therapy for metastatic gastric, GEJ and esophageal cancer.
  • Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of gastric, GEJ and esophageal cancer, and recognize how these strategies should be integrated into current treatment algorithms.
  • Evaluate the biological rationale for the investigation of claudin 18.2 as a therapeutic target in gastric/GEJ cancer, and assess available data with novel strategies directed at this emerging biomarker.
  • Optimize the use of adjuvant chemotherapy for patients with localized colorectal cancer (CRC), considering various clinical and biological factors, such as age, performance status and stage, and the potential relevance of molecular residual disease.
  • Develop an understanding of newly validated biomarkers of response (eg, HER2, microsatellite instability/mismatch repair deficiency, KRAS G12C) found in metastatic CRC (mCRC), and consider the implications for molecular testing and clinical care.
  • Counsel patients with microsatellite instability-high/mismatch repair-deficient mCRC regarding the risks, benefits and optimal use of available immunotherapeutic agents and regimens.
  • Appreciate published and recently presented research data documenting the efficacy of KRAS G12C inhibition for patients with relapsed/refractory mCRC and a KRAS G12C mutation, and consider the potential role of this therapeutic strategy.
  • Understand available research guiding the selection and sequencing of later-line therapeutic options for patients with multiregimen-relapsed mCRC, considering the implications of recently presented Phase III data sets and new FDA approvals.
  • Recall available data with novel HER2-targeted agents and strategies for patients with HER2-overexpressing gastric/GEJ and colorectal cancer, and identify candidates who may be appropriate for these approaches.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 2 contact hours is provided by Research To Practice.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA Certification
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Griffie and Ms Kuhlman — No relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr ShahContracted Research: Bristol Myers Squibb, Merck, Oncolys BioPharma. Dr StricklerAdvisory Committees: AbbVie Inc, Agenus Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Natera Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Xilio Therapeutics; Contracted Research: AbbVie Inc, Amgen Inc, A*STAR D3, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, GSK, Leap Therapeutics Inc, Lilly, Novartis, Pfizer Inc, Revolution Medicines; Data and Safety Monitoring Boards/Committees: AbbVie Inc, BeiGene Ltd, GSK, Pfizer Inc; Stock Options — Private Company: Triumvira Immunologics.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, and Taiho Oncology Inc.

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence Ballroom (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2024 ONS Congress and is connected to the Walter E Washington Convention Center by an underground concourse.


This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastroesophageal and colorectal cancers.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.

Registration for this event is independent of registration for the 2024 ONS Congress.

IN-PERSON Registration for nurses and other healthcare providers

I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.